[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369186-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369186-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","evaluation-of-a-norcantharidin-nanoemulsion-efficacy-for-treating-b16f1-induced-melanoma-in-a-syngeneic-murine-model","Evaluation of a Norcantharidin Nanoemulsion Efficacy for Treating B16F1-Induced Melanoma in a Syngeneic Murine Model","","Melanoma is a lethal cancer arising from melanocytes, and surgery is the primary treatment, yet many patients are not eligible for operative procedures. To address the need for new or complementary therapies, a norcantharidin-containing nanoemulsion was developed and assessed in vivo using a syngeneic graft murine model. The study compared a surgical-excision simulation with nanoemulsion administration as a potential adjuvant option. Treatment significantly reduced melanoma lesion growth rate versus controls at both days 20 and 30. Norcantharidin bioavailability in serum was detectable at 0.1–0.18 mg/mL in treated groups, and histopathological evaluations of excised tumors showed significant differences in tumor size, mitosis rate, lymphocytic infiltration, and quantitative multispectral imaging metrics relative to controls.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/evaluation-of-a-norcantharidin-nanoemulsion-efficacy-for-treating-b16f1-induced-melanoma-in-a-syngeneic-murine-model/369186/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/evaluation-of-a-norcantharidin-nanoemulsion-efficacy-for-treating-b16f1-induced-melanoma-in-a-syngeneic-murine-model/369186.png","ImageObject",300,407,{"name":42,"@type":43},"Aria","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main goal of this study on norcantharidin nanoemulsion?","Question",{"text":63,"@type":64},"To develop and evaluate a norcantharidin-containing nanoemulsion in vivo for treating B16F1-induced melanoma in a syngeneic murine model, including its potential role as an adjuvant therapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the treatment affect melanoma lesion growth over time?",{"text":68,"@type":64},"Treated groups showed a significant decrease in melanoma lesion growth rate compared with the control group at both the 20th and 30th days of treatment.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence supported the systemic availability and tissue effects of norcantharidin?",{"text":72,"@type":64},"Norcantharidin was detectable in serum samples at 0.1–0.18 mg/mL in treated groups, and histopathological analysis of tumors showed significant differences versus control, including size, mitosis rate, and lymphocytic infiltration.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369186,1790764330,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Article  \nEvaluation of a Norcantharidin Nanoemulsion Efficacy for  \nTreating B16F1-Induced Melanoma in a Syngeneic Murine Model  \nGabriel Martínez-Razo 1, Patrícia C. Pires 2,3,4, Angélica Avilez-Colin 1, María Lilia Domínguez-López 1, Francisco Veiga 2,3, Eliezer Conde-Vázquez 5, Ana Cláudia Paiva-Santos 2,3, * and Armando Vega-López 1, *  \nAcademic Editors: Domenico Mallardo, Debora Basile, Maria Grazia Vitale and Jose Carlos Garcia-Borron  \nReceived: 19 December 2024  \nRevised: 21 January 2025  \nAccepted: 28 January 2025  \nPublished: 30 January 2025  \nCitation: Martínez-Razo, G.; Pires, P.C.; Avilez-Colin, A.;  \nDomínguez-López, M.L.; Veiga, F.; Conde-Vázquez, E.; Paiva-Santos, A.C.; Vega-López, A. Evaluation of a Norcantharidin Nanoemulsion Efficacy for Treating B16F1-Induced Melanoma in a Syngeneic Murine Model. Int. J. Mol. Sci. 2025, 26, 1215 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms26031215  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Laboratorio de Toxicología Ambiental, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Unidad Profesional Zacatenco, Mexico City 07738, Mexico  \n2 Department of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Azinhaga Sta. Comba, 3000-548 Coimbra, Portugal; [patriciapires@ff.uc.pt](patriciapires@ff.uc.pt) (P.C.P.)  \n3 LAQV, REQUIMTE, Department of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Azinhaga Sta. Comba, 3000-548 Coimbra, Portugal  \n4 Health Sciences Research Centre (CICS-UBI), University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal  \n5 Hospital Bicentenario de la Independencia del Instituto de Salud de Trabajadores del Estado ISSSTE, Ciruelos 4, Lázaro Cárdenas, Tultitlán de Mariano Escobedo 54916, Mexico  \n* Correspondence: [acsantos@ff.uc.pt](acsantos@ff.uc.pt) (A.C.P.-S.); [avegadv@yahoo.com.mx](avegadv@yahoo.com.mx) (A.V.-L.)  \nAbstract: Melanoma, a lethal type of cancer originating from melanocytes, is the leading cause of death among skin cancers. While surgical excision of the lesions is the primary treatment for melanoma, not all cases are candidates for surgical procedures. New treatments and complementary options are necessary, given the increasing diagnosis rate. In the present study, a norcantharidin-containing nanoemulsion was developed and evaluated in vivo using a syngeneic graft murine model. Norcantharidin is the demethylated analog of cantharidin, known for its anticancer properties. Our model contemplates surgical excision surgery simulating the standard treatment and the role of the nanoemulsion as a potential adjuvant therapy. We observed a significant decrease in the growth rate of the melanoma lesion in the treated groups compared to the control group, both at the 20th and 30th days of treatment. Moreover, we evaluated the drug bioavailability in serum samples, and the results showed that norcantharidin was detectable in a range of 0.1 to 0.18 mg/mL in the treated groups. Furthermore, histopathological analysis was performed on the amputated tumors, where significant differences were found regarding size, mitosis rate, lymphocytic infiltration, and multispectral quantitative image analysis compared to the control group. If more clinical studies are conducted, the norcantharidin-containing nanoemulsion could be a potential alternative or adjuvant therapy. Topical nanosystems can become or complement standard therapies, which is needed as melanoma affects not only in terms of mortality but also the patient’s morbidity and life quality.  \nKeywords: melanoma; nanoemuls","cbCaifRoOzw60wkF","https://ap.wps.com/l/cbCaifRoOzw60wkF","pdf",3438823,"English","# Introduction\n## Melanoma burden and prognosis\n## Clinical detection and diagnostic challenges\n## Standard treatment and limits of surgery","[{\"question\":\"What was the main goal of this study on norcantharidin nanoemulsion?\",\"answer\":\"To develop and evaluate a norcantharidin-containing nanoemulsion in vivo for treating B16F1-induced melanoma in a syngeneic murine model, including its potential role as an adjuvant therapy.\"},{\"question\":\"How did the treatment affect melanoma lesion growth over time?\",\"answer\":\"Treated groups showed a significant decrease in melanoma lesion growth rate compared with the control group at both the 20th and 30th days of treatment.\"},{\"question\":\"What evidence supported the systemic availability and tissue effects of norcantharidin?\",\"answer\":\"Norcantharidin was detectable in serum samples at 0.1–0.18 mg/mL in treated groups, and histopathological analysis of tumors showed significant differences versus control, including size, mitosis rate, and lymphocytic infiltration.\"}]","Evaluation of a Norcantharidin Nanoemulsion Efficacy for Treating B16F1-Induced Melanoma in a Syngeneic Murine Model | PDF",1790181284,48,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f927e4f475726ffc5125cb8426307504.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e8e352f49a4dc578c2202aa2669ccc2e.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9760b7157efe4a0e1da4963b531d95a1.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f62d810f823e731b339fcbcd66c90423.webp",980,1385]